Trial
NCT05970263
IKANOS: Breztri Maintenance Versus Any Non-Triple Inhaled Therapy After Hospitalization for a COPD Exacerbation in the US
Phase IVWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
AstraZeneca
Collaborators
IQVIA Pty Ltd; Premier Inc
Condition
COPD
Intervention
Budesonide/glycopyrrolate/formoterol fumarate (Breztri Aerosphere) 320 μg/18 μg/9.6 μg administered as two inhalations, twice daily.
Why stopped
Recruitment challenges
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-02-01